MDCO News and Press, The Medicines Company From 10/30/19

- Inclisiran’s pivotal Phase 3 LDL-C lowering clinical trials program successfully completed, and each study met all primary and secondary endpoints - Phase 3 data reinforced durable, potent efficacy and excellent safety - ORION-11 results presented at ESC Congress 2019 ...

The Medicines Company (NASDAQ: MDCO) will host a conference call and audio webcast on Wednesday, October 30, 2019 at 8:30 a.m. EDT to discuss its third quarter 2019 financial results and operational developments. The conference call may be accessed by telephone as follows: A live audi...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

The Medicines Company ( MDCO ) currently has a market capitalization over $4 billion despite having consistently negative earnings, with the timing of profitability an unknown. The biotechnology company's value is dependent on its late-stage clinical drug inclisiran. The company previously had...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

Mereo Biopharma (NASDAQ: MREO ) initiated with Outperform rating and $8 (177% upside) price target at SVB Leerink. More news on: Mereo BioPharma Group plc, The Medicines Company, UnitedHealth Group Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3 rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York. The Company is scheduled to participate in a “fireside chat” discussion at 8:00 a.m. Eastern Daylight Time. ...

The Medicines Company (NASDAQ: MDCO) announced last week that recent trial data showed positive results for its flagship cholesterol drug , inclisiran. Shares of the company, which has a $3.82 billion market cap, shot up 9.3% in response to the news, and although the stock has given back mo...

The Medicines Company (NASDAQ: MDCO) is up 161% this year, thanks in large part to the success of its cholesterol-lowering drug inclisiran. In August, the company announced that one of its late-stage clinical trials, Orion-11, was positive, which was followed by a presentation a few days ...